Ginkgo & OpenAI Slash Protein Synthesis Costs by 40%
Ginkgo Bioworks teams up with OpenAI to cut cell-free protein synthesis costs by 40% using AI and cloud lab automation.
Already have an account? Sign in.
Ginkgo Bioworks teams up with OpenAI to cut cell-free protein synthesis costs by 40% using AI and cloud lab automation.
New drug combo helps lymphoma patients live longer without worsening disease, cutting risk by ~60%—without chemotherapy.
Abivax advances toward Q4 2026 NDA filing with encouraging remission and safety results.
Phase 2 trials in early Parkinson’s to start Q3 2026 in U.S. & Europe after strong Phase 1 biomarker and safety data.